Method of treating inflammatory intestinal diseases containing as the ingredient IL-6 receptors antibodies

• US 6,723,319 B1
• Filed: 09/14/2000
• Issued: 04/20/2004
• Est. Priority Date: 03/17/1998
• Status: Expired due to Term

• Current Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG), Tadamitsu Kishimoto
• Original Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG), Tadamitsu Kishimoto
• Inventors: Kishimoto, Tadamitsu, Ito, Hiroaki, Yamamoto, Mitsunari
• Primary Examiner(s): Mertz, Prema
• Application Number:
  US09/646,188
• Time in Patent Office: 1,314 Days
• Field of Search: 514/2, 514/8, 514/12, 514/885, 530/387.1, 530/388.22, 530/388.23, 530/389.2, 435/375, 424/85.2, 424/134.1, 424/139.1, 424/141.1, 424/142.1, 424/143.1, 424/130.1
• US Class Current: 424/143.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/12 Antidiarrhoeals
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons

Abstract

A preventive or therapeutic agent for treating bowel disease, including Crohn'"'"'s disease and ulcerative colitis, where the agent has as an active ingredient an antibody directed against IL-6 receptor which is an interleukin-6 antagonist.

Claims

1. A method of treating inflammatory bowel disease, said method comprising administering an anti-interleukin-6 receptor antibody, wherein the antibody used is the monoclonal antibody, PM-1 against human IL-6 receptor.

3. A method of treating inflammatory bowel disease according to claim 1 or 2, wherein the inflammatory bowel disease is Crohn'"'"'s disease or ulcerative colitis.

4. The method according to claim 1, wherein the monoclonal antibody PM-1 is a humanized antibody.

2. A method of treating inflammatory bowel disease, said method comprising administering an anti-interleukin-6 receptor antibody, wherein the antibody used is the monoclonal antibody MR16-1 against human IL-6 receptor.